PT  - JOURNAL ARTICLE
AU  - Ahmed, Iftekhar
AU  - Hasan, Maruf
AU  - Akter, Rahima
AU  - Sarkar, Bidduth Kumar
AU  - Rahman, Marufa
AU  - Sarker, Md Samun
AU  - Samad, Mohammed A.
TI  - Behavioral preventive measures and the use of medicines and herbal products among the public in response to Covid-19 in Bangladesh: A cross-sectional study
AID  - 10.1101/2020.08.15.20175513
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.15.20175513
4099  - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175513.short
4100  - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175513.full
AB  - The present study was conducted to assess the behavioral preventive measures and the use of medicines and herbal foods/products among the public in response to Covid-19. A cross-sectional survey was conducted from 27 June to 20 July 2020, and 1222 people participated. Kruskal-Wallis test was used to identify the differences in behavioral preventive practices across different demographic categories. To identify the factors associated with the use of preventive medicines and herbal foods/products, multivariable logistic regression was performed. Most participants adopted the recommended preventive practices such as washing hands more frequently (87.5%), staying home more often (85.5%), avoiding crowds (86%), and wearing masks (91.6%). About half of the smokers reported a decreased rate of smoking during the pandemic. Also, 14.8% and 57.6% of the participants took medicines and herbal foods/products as preventive measures against Covid-19. Arsenicum album and Zinc supplements were the most commonly used preventive medicines. Gender, age, and fear of Covid-19 were significantly associated with the use of both preventive medicines and herbal products. For the management of Covid-19 related symptoms, Paracetamols, Fexofenadine, and Zinc supplements were used most often. Most participants sought information from non-medical sources while using medicines and herbal products. Moreover, potentially inappropriate and unnecessary use of drugs were identified.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was reviewed and approved by the Antimicrobial Resistance Action Center (ARAC), Animal Health Research Division, Bangladesh Livestock Research Institute (BLRI), Bangladesh (Approval no: ARAC:15/06/2020:03).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data collected, without personally identifiable information, is available upon request to the corresponding author